A Leishmania display platform for expression of human antibodies and glycoproteins

Immunoprecise Antibodies （IPA）是一家位于不列颠哥伦比亚省维多利亚的公司，专门开发和生产小鼠和兔单克隆抗体（mab）。为了扩大其在抗体和重组蛋白生产领域的竞争力，IPA正在探索新的战略，以提供高质量治疗或研究抗体的生产更快的转变。在多克隆或单克隆抗体的生产中，最耗时的步骤之一是宿主动物的免疫和增强；这通常需要50-60天。为了最大限度地减少这种滞后时间，IPA有兴趣开发一种新的抗体生产平台，该平台可以绕过免疫步骤，生产具有正确糖基化模式的全长igg抗体。实施这一策略将涉及开发一种新的双电子载体，用于在原虫利什曼原虫中创建一个表面显示IgG文库。克隆表达的IgG抗体识别感兴趣的抗原，可以很容易地分离使用生物筛选方法。使用利什曼原虫的一个主要优势是这种生物的糖基化模式与在人和兔IgG抗体上观察到的非常相似。该项目将为最终创建人体IgG表面显示库提供所需的原理数据证明。

Immunoprecise Antibodies (IPA) is a Victoria, BC based company with expertise in development andproduction of murine and rabbit monoclonal antibodies (mAbs). To expand its competitive foot print in theantibody and recombinant protein production sector, IPA is exploring new strategies that will provide a morerapid turn around in the production of high quality therapeutic or research antibodies. In the production ofpolyclonal or monoclonal antibodies, one of the most time consuming steps is the immunization and boostingof host animals; which typically requires 50-60 days. To minimize this lag time IPA is interested in developinga new antibody production platform that circumvents the immunization step and will produced full length IgGantibodies that have the correct glycosylation patterns. Implementing this strategy will involve the developmentof an novel bicistronic vectors that will be used to create a surface display IgG library in the protozoanorganism Leishmania. Clones expressing the an IgG antibody that recognizes an antigen of interest can easilybe isolated using a biopanning approach. A major advantage for using Leishmania is that this organism hasglycosylation patterns that closely resemble thos observed on human and rabbit IgG antibodies. This projectwill provide that proof of principle data require for the ultimate creation of a human IgG surface display library.